News

Potential Gene Therapy TSHA-102 Does Well in Animal Study

TSHA-102, an experimental gene therapy for Rett syndrome, safely and effectively normalized levels of MeCP2 — the protein missing or defective in most Rett patients — in the brain and significantly improved survival in a mouse model of the disease, a study shows. Notably, the data suggest this investigational treatment can…

Daytime Teeth Grinding Means More Dental Work

People with Rett syndrome who grind their teeth during the day had a higher incidence of dental treatment, particularly restorations, than those who did not, an international database study reported.  The findings also showed that patients fed orally had more dental…

Board Recommends All Anavex 2-73 Trials Proceed

An independent monitoring board has recommended that all three ongoing clinical trials of Anavex 2-73 (blarcamesine), an investigational treatment for Rett syndrome, continue without changes, based on a review of interim safety data. Anavex Life Sciences, the medication’s developer, announced the decision in a press release. Data…